Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Antengene Biologics Limited is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner within 1 distinct art unit. The limited number of pending matters reflects a narrow current prosecution pipeline, with all activity concentrated in a single technical review process.
The busiest examiner for the company is MOSELEY II, NELSON B, who has 1 busiest examiner pending office action. This single examiner is responsible for the 1 pending office action currently active for the portfolio. Since the company has 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is presently focused on the requirements of this specific examiner. The outcome of the company's current efforts at the USPTO depends on the evaluation of this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559795 | NOVEL ANTI-CD276 ANTIBODIES AND THE USES THEREOF | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18559795 | NOVEL ANTI-CD276 ANTIBODIES AND THE USES THEREOF | MOSELEY II, NELSON B | 1642 | §112 | Non-Final OA | — | Pending | Nov 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAntengene Biologics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nelson B Moseley II has the most, with 1 of Antengene Biologics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
